Ironwood Pharmaceuticals (IRWD) Non-Current Assets (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Non-Current Assets across 17 years of filings, most recently posting $85.9 million for Q2 2026.

• In Q2 2026, Non-Current Assets fell 43.17% year-over-year to $85.9 million; the TTM figure through Jun 2026 stood at $433.1 million (down 37.88% YoY), while the FY2025 annual figure was $122.7 million, down 27.18% from the prior year.
• Non-Current Assets came in at $85.9 million for Q2 2026 at Ironwood Pharmaceuticals, down from $102.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $373.3 million in Q1 2022 to a low of $85.9 million in Q2 2026.
• Average Non-Current Assets over 5 years is $225.2 million, with a median of $224.0 million recorded in 2024.
• Year-over-year, Non-Current Assets surged 510.95% in 2022 and plunged 43.17% in 2026.
• Over 5 years, Non-Current Assets stood at $319.9 million in 2022, then retreated by 25.67% to $237.8 million in 2023, then dropped by 29.12% to $168.5 million in 2024, then retreated by 27.18% to $122.7 million in 2025, then slipped by 29.98% to $85.9 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $85.9 million in Q2 2026, $102.3 million in Q1 2026, and $122.7 million in Q4 2025.